天港医诺 - TG ImmunoPharma

Our Journey

2020.10

Our Journey

2021.08

Our Journey

2021.11

Our Journey

2022.04

Pre-Series A Financing Round lead by Casstar and Innoval Capital, other investors include Hefei Industry Investment Capital, Efung Capital, Tiantu Capital and Guoyuan Innovating Investment

Awarded the National Scientific and Technological Small and Medium-sized Enterprise

Our Journey

2022.12

TG ImmunoPharma (TGI) announces FDA clearance of IND application for TGI-2, a novel anti-PVRIG therapeutic antibody

Awarded the VB-Find Award: the Top 100 most innovative medical technology products in the year of 2022

Our Journey

2023.01

Awarded the "Science and Technology Innovation Award" of Jingkai District, Hefei

Our Journey

2023.04

TG ImmunoPharma announces NMPA clearance of IND application for TGI-2, a novel anti-PVRIG therapeutic antibody

Our Journey

2023.06

TG ImmunoPharma announces FDA clearance for clinical trial of TGI-6 bispecific antibody

Our Journey

2023.10

TGI announces NMPA clearance of IND application for TGI-6

Our Journey

2023.11

TG ImmunoPharma Announces FDA Clearance for Clinical Trial of TGI-5 monoclonal Antibody

Our Journey

2024.01

First-Patient-In: TGI-6 developed by TG ImmunoPharma Started Phase I Clinical Trial in the China

Our Journey

2024.03

TGI announces NMPA clearance of IND application for TGI-5

Click timeline or arrow to view more

Science

TG ImmunoPharma (TGI) works on an innovative immunotherapeutic approach against cancer.
This treatment model aims at restoring or renormalizing the defense, surveillance and homeostasis of immune system. Evidences have demonstrated that immunotherapy could lead to durable efficacy or even complete cure in some patients who have failed all available conventional therapies.

Technology